Cambridge, United States
Rubius Therapeutics, founded in 2014 and headquartered in the United States, is at the forefront of biotechnology by innovatively repurposing red blood cells as medicines. With their slogan, "Red blood cells are no longer just for carrying oxygen. At Rubius Therapeutics, we are transforming them into medicines," the company encapsulates its groundbreaking work in cellular medicine.
The company's proprietary RED PLATFORM™ allows for the genetic engineering of Red Cell Therapeutics™ (RCT), which are potent, ready-to-use therapies targeting cancer and autoimmune diseases. Currently, Rubius Therapeutics is conducting Phase 1/2 clinical trials for RTX-240 and RTX-224, focusing on advanced solid tumors including non-small cell lung cancer, renal cell carcinoma, and more.
Having secured a $200.00M post-IPO equity investment in March 2021, Rubius Therapeutics is poised for future growth within the biotechnology sector, presenting compelling investment opportunities given its innovative approach and ongoing clinical advancements.
